| P50 | author | Lawrence E Heisler | Q50211251 |
| | Jason Moffat | Q83455827 |
| | Iain M Wallace | Q37393604 |
| P2093 | author name string | Saranya Kittanakom | |
| | Guri Giaever | |
| | Anthony Arnoldo | |
| | Anuradha Surendra | |
| | Kevin R Brown | |
| | Corey Nislow | |
| | Dax Torti | |
| | Tada Kunavisarut | |
| P2860 | cites work | A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity. | Q40056489 |
| | Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells | Q40324022 |
| | Synthesis and antitumor activity of sulfur-containing 9-anilinoacridines | Q40440109 |
| | Genomic profiling of drug sensitivities via induced haploinsufficiency. | Q41614030 |
| | Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients | Q42722677 |
| | Lessons from 60 years of pharmaceutical innovation | Q43447062 |
| | Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects | Q43566532 |
| | Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas | Q43632421 |
| | Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity | Q43879115 |
| | Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose. | Q46038766 |
| | Sulforhodamine B colorimetric assay for cytotoxicity screening. | Q51032435 |
| | The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. | Q53159003 |
| | Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Q57412648 |
| | Antifertility treating with long term gossypol | Q77062601 |
| | Aberrant expression of the apoptosis-related proteins BAK and MCL1 in T cells in multiple sclerosis | Q83275600 |
| | Mcl1 becomes ubiquitin-ous: new opportunities to antagonize a pro-survival protein | Q83968238 |
| | A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair | Q24337655 |
| | Cellular and molecular mechanisms of metformin: an overview | Q27013561 |
| | Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes | Q28238338 |
| | Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia | Q28254349 |
| | Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast | Q28473277 |
| | The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 |
| | Quantitative phenotyping via deep barcode sequencing. | Q30482301 |
| | Median absolute deviation to improve hit selection for genome-scale RNAi screens | Q33316277 |
| | A comparative analysis of DNA barcode microarray feature size | Q33510271 |
| | A comprehensive platform for highly multiplexed mammalian functional genetic screens | Q33891511 |
| | Targeting the cancer kinome through polypharmacology | Q33893019 |
| | Highly-multiplexed barcode sequencing: an efficient method for parallel analysis of pooled samples | Q34020284 |
| | Trends in the exploitation of novel drug targets | Q34205159 |
| | Systems approaches to polypharmacology and drug discovery | Q34746314 |
| | Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes | Q34862358 |
| | Chemogenomic profiling: identifying the functional interactions of small molecules in yeast | Q35554300 |
| | Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia | Q35564841 |
| | Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis | Q35842470 |
| | The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 |
| | Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma | Q36146025 |
| | BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists | Q36948615 |
| | Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen | Q36954859 |
| | Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. | Q37163339 |
| | Molecular networks in drug discovery. | Q37798843 |
| | The importance of new companies for drug discovery: origins of a decade of new drugs | Q37804687 |
| | Metformin and cancer therapy. | Q37962127 |
| | Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2. | Q39455093 |
| | Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma | Q39741662 |
| | An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells | Q39923279 |
| P4510 | describes a project that uses | limma | Q112236343 |
| P433 | issue | 8 | |
| P304 | page(s) | 1375-1387 | |
| P577 | publication date | 2013-08-07 | |
| P1433 | published in | G3 | Q5512701 |
| P1476 | title | Miniature short hairpin RNA screens to characterize antiproliferative drugs | |
| P478 | volume | 3 | |